Anivance AI

Anivance AI is transforming preclinical research with AI-driven biotechnology, making drug development faster, smarter, and more predictive. Led by a world-class team of experts from MIT, the Terasaki Institute, and IBM, they are actively advancing their technologies with industry-leading pharmaceutical partners. Their main solution is an AI agent-powered Organ-on-Chip (OoC) system that aims to shift from human-heavy workflows to fully AI-driven autonomous experimentation, accelerating decision-making and improving the precision of therapeutic development.